- 2600 Stemmons Freeway,
- Suite 176
- Dallas, TX 75207-2107
- Tel: (214) 905-5100
- Fax: (214) 905-5101
Access Pharmaceuticals is an emerging biopharmaceutical company specializing in products for cancer and supportive care. Access currently has one product approved for marketing in the US, Europe, China, and S. Korea, one product in Phase II clinical development, three products in preclinical development. Several of the company's products are based on Access' proprietary nanopolymer technologies which provide enhanced drug delivery options for both new and approved pharmaceutical active ingredients.
While its primary focus is in oncology, Access' drug delivery technologies also yield candidates that enable and enhance the absorption of drugs by exploiting the body's own vitamin B-12 absorption system. Mucositis is a frequent side-effect of cancer therapy for which there is no established treatment. MuGard is Access' approved proprietary nanopolymer formulation for the management of mucositis. This ready-to-use rinse provides a soothing oral coating. A clinical study has shown that when MuGard is used by patients from the start of cancer therapy, the incidence and severity of mucositis are reduced. For more information, visit www.MuGard.com
Access is focusing its development effort on its Cobalamin technology. Cobalamin is Access' proprietary nanopolymer oral drug delivery technology. Using a 'Trojan Horse' approach, the technology uses the body's natural vitamin B12 uptake mechanism in the gut to transport drugs that otherwise would have little or no oral bioavailability. The company is currently developing products for the oral delivery of insulin and human growth hormone (HGH), and is collaborating with a number of companies to develop additional formulations of various other pharmaceutically-active compounds. Cells involved in certain diseases such as cancer often have an increased demand for vitamin B12 which results in an large increase in receptors for vitamin B12 on their surface. Another aspect of the Cobalamin technology therefore focuses on increasing the amount of drugs reaching sites of disease by making use of this higher receptor density. Application of the Cobalamin technology to enhance oral drug delivery has been named CobOral®, while application of the technology to target disease sites has been named CobaCyte®.